Top Markets
#1 Wiki Cat Wiki Cat +37.63%
#2 Siren Siren +36.28%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.75%
#4 Velvet Velvet +18.68%
#5 aPriori aPriori +18.66%
#6 PulseChain PulseChain +17.42%
#7 Ribbita by Virtuals Ribbita by Virtuals +15.96%
#8 Janction Janction +14.74%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +14.55%
#10 The Grays Currency The Grays Currency +14.37%
Coin of the day
Wiki Cat Wiki Cat
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Rang in Aktien #30914
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aktienkurs
$0.343985
Marktkapitalisierung
$15.40M
Veränderung (1 Tag)
3.94%
Veränderung (1 Jahr)
-25.19%
Land
BE
Handel Celyad Oncology S.A. (CYAD)

Kategorie

Healthcare
Umsatz von Celyad Oncology S.A. (CYAD)
Umsatz im Aug 2026 TTM: 0
Laut den aktuellen Finanzberichten von Celyad Oncology S.A. beträgt der derzeitige Umsatz des Unternehmens (TTM) 0. Im Jahr 2026 erzielte das Unternehmen einen Umsatz von 0 gleich wie dem Umsatz im Jahr 2026, der 0 betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Celyad Oncology S.A. von 2026 bis 2026
Umsatz am Ende jedes Jahres
Jahr Umsatz ändert
Nicht genügend Daten für die angegebenen Daten.
Umsatz vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Umsatz Umsatzunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE